Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Biogen Idec ( BIIB) upgraded at Credit Suisse from Neutral to Outperform. $126 price target. Estimates also boosted, given higher expectations for BG12.

Boston Scientific ( BSX) rated new Buy at Stifel Nicolaus. $9 price target. Earnings growth could soon begin to accelerate.

F5 Networks ( FFIV) upgraded at Barclays from Equal Weight to Overweight. $125 price target. Estimates also increased through 2012. F5's revenue pipeline and market are healthy.

Forest Oil ( FST) upgraded at Stifel from Hold to Buy, Stifel Nicolaus said. $34 price target. Stock has pulled back to an attractive level.

Hexcel ( HXL) upgraded at Keybanc from Hold to Buy. $28 price target. Company is leveraged to higher commercial aerospace demand.

Polo Ralph Lauren ( RL) rated new Outperform at Wells. Recent investments should help future growth.

Synovus Financial ( SNV) downgraded at Wunderlich from Buy to Hold. $2.50 price target. Company still faces significant earnings headwinds.

Susquehanna ( SUSQ) upgraded at KBW from Market Perform to Outperform, Keefe, Bruyette & Woods said. Valuation call, based on a $10 price target.

Western Refining ( WNR) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $24 price target. Company is leveraged to a wider Brent-WTI spread.

VCA Antech ( WOOF) rated new Outperform at Barrington Research. $28 price target. Company generates significant free cash flow.

End of report.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways

Perils of Politics: Cramer's 'Mad Money' Recap (Monday 7/31/17)

These Stocks Are Ready to Reverse Course

Modi's Visit to Meet Trump Focuses Big Spotlight on the H-1B Visa Debate

Cramer: These Sectors Look Bullish (Part III)